C
Catriona M. McNeil
Researcher at University of Sydney
Publications - 103
Citations - 15948
Catriona M. McNeil is an academic researcher from University of Sydney. The author has contributed to research in topics: Breast cancer & Pembrolizumab. The author has an hindex of 36, co-authored 102 publications receiving 12982 citations. Previous affiliations of Catriona M. McNeil include Westmead Hospital & Garvan Institute of Medical Research.
Papers
More filters
Journal ArticleDOI
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert,Caroline Robert,Caroline Robert,Jacob Schachter,Georgina V. Long,Ana Arance,Jean-Jacques Grob,Laurent Mortier,Laurent Mortier,Adil Daud,Matteo S. Carlino,Catriona M. McNeil,Michal Lotem,James Larkin,Paul Lorigan,Bart Neyns,Christian U. Blank,Omid Hamid,Christine Mateus,Christine Mateus,Ronnie Shapira-Frommer,Ronnie Shapira-Frommer,Michele Kosh,Honghong Zhou,Nageatte Ibrahim,Scot Ebbinghaus,Antoni Ribas +26 more
TL;DR: The anti-PD-1 antibody pembrolizumab prolonged progression-free survival and overall survival and had less high-grade toxicity than did ipilimumab in patients with advanced melanoma.
Journal ArticleDOI
Nivolumab in previously untreated melanoma without BRAF mutation.
Caroline Robert,Georgina V. Long,Benjamin Brady,Caroline Dutriaux,Michele Maio,Laurent Mortier,Jessica C. Hassel,Piotr Rutkowski,Catriona M. McNeil,Ewa Kalinka-Warzocha,Kerry J. Savage,Micaela Hernberg,Céleste Lebbé,Julie Charles,Catalin Mihalcioiu,Vanna Chiarion-Sileni,Cornelia Mauch,Francesco Cognetti,Ana Arance,Henrik Schmidt,Dirk Schadendorf,Helen Gogas,Lotta Lundgren-Eriksson,Christine Horak,Brian Sharkey,Ian M. Waxman,Victoria Atkinson,Paolo A. Ascierto,Abstr Act +28 more
TL;DR: Nivolumab was associated with significant improvements in overall survival and progression-free survival, as compared with dacarbazine, among previously untreated patients who had metastatic melanoma without a BRAF mutation.
Journal ArticleDOI
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
Jacob Schachter,Antoni Ribas,Georgina V. Long,Ana Arance,Jean-Jacques Grob,Laurent Mortier,Adil Daud,Matteo S. Carlino,Catriona M. McNeil,Michal Lotem,James Larkin,Paul Lorigan,Bart Neyns,Christian U. Blank,Teresa M. Petrella,Omid Hamid,Honghong Zhou,Scot Ebbinghaus,Nageatte Ibrahim,Caroline Robert +19 more
TL;DR: The final protocol-specified survival analysis as mentioned in this paper showed that pembrolizumab continued to provide superior overall survival versus ipilimumab, with no difference between the two dosing schedules.
Journal ArticleDOI
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
Caroline Robert,Antoni Ribas,Jacob Schachter,Ana Arance,Jean-Jacques Grob,Laurent Mortier,Adil Daud,Matteo S. Carlino,Catriona M. McNeil,Michal Lotem,James Larkin,Paul Lorigan,Bart Neyns,Christian U. Blank,Teresa M. Petrella,Omid Hamid,Shu Chih Su,Clemens Krepler,Nageatte Ibrahim,Georgina V. Long +19 more
TL;DR: Pembrolizumab improved progression-free survival and overall survival versus ipilimumab in patients with advanced melanoma and is now a standard of care in the first-line setting, however, the optimal duration of anti-PD-1 administration is unknown.
Journal ArticleDOI
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial
Paolo A. Ascierto,Michele Del Vecchio,Caroline Robert,Andrzej Mackiewicz,Vanna Chiarion-Sileni,Ana Arance,Céleste Lebbé,Lars Bastholt,Omid Hamid,Piotr Rutkowski,Catriona M. McNeil,Claus Garbe,Carmen Loquai,Brigitte Dréno,Luc Thomas,Jean-Jacques Grob,Gabriella Liszkay,Marta Nyakas,Ralf Gutzmer,Joanna Pikiel,Florent Grange,Christoph Hoeller,Virginia Ferraresi,Michael Smylie,Dirk Schadendorf,Laurent Mortier,Inge Marie Svane,Delphine Hennicken,Anila Qureshi,Michele Maio +29 more
TL;DR: In patients with advanced melanoma, ipilimumab 10 mg/kg resulted in significantly longer overall survival, but with increased treatment-related adverse events, while the treatment landscape for advanced melanomas has changed since this study was initiated.